Product image of Marvelon (Desogestrel, Ethinylestradiol) supplied by GNH India

Marvelon

Active Ingredient:
Desogestrel, Ethinylestradiol
Origin:
EU

Marvelon (Desogestrel, Ethinylestradiol)

Desogestrel, the active ingredient in Marvelon, is a combined oral contraceptive presented as a desogestrel 150 µg / ethinylestradiol 30 µg tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus.

GNH India supplies Marvelon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality for global contraceptive needs and ensuring regulatory compliance across markets.

Manufacturer / TM Owner

Organon Polska Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Marvelon, a combined oral contraceptive, is used to prevent pregnancy by regulating the hormonal cycle.

  • Contraception: provides reliable protection against unintended pregnancy when taken as directed.
  • Menstrual cycle regulation: helps achieve regular withdrawal bleeding and reduces cycle variability.
  • Acne treatment: may improve mild to moderate acne associated with hormonal fluctuations.

How It Works

  • Desogestrel and ethinylestradiol act together to suppress the mid‑cycle surge of luteinising hormone, preventing ovulation. The estrogen component stabilises the endometrium and enhances cervical mucus viscosity, while the progestogen component further thickens mucus and induces endometrial changes that reduce the likelihood of implantation.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: temporary swelling or discomfort.
  • Headache: occasional tension‑type headaches.
  • Spotting: irregular light bleeding between periods.
  • Weight gain: slight increase in body weight.
  • Mood changes: mild emotional fluctuations.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins.
  • Arterial thrombosis: clot formation in arteries, potentially leading to stroke.
  • Hypertension: new or worsening high blood pressure.
  • Liver disorders: jaundice or hepatic dysfunction.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Visual disturbances: sudden vision changes or loss.

Precautions & Warnings

Before initiating Marvelon, consider the following precautions:

  • Assess thrombotic risk: evaluate personal and family history of clotting disorders.
  • Screen for hypertension: measure blood pressure and manage elevated readings.
  • Avoid smoking: counsel women over 35 who smoke to discontinue use.
  • Review concomitant medications: identify drugs that may alter hormonal efficacy.
  • Pregnancy contraindication: do not use in confirmed or suspected pregnancy.
  • Store at ambient temperature: keep below 25 °C in the original pack, protect from moisture.

Avoid Interactions

Marvelon may interact with several medicines that affect hormone metabolism.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive effectiveness.
  • Protease inhibitors (e.g., ritonavir): can lower hormone levels, increasing failure risk.
  • St. John’s wort: may diminish plasma concentrations of estrogen and progestogen.

Moderate Interactions (Monitor Closely)

  • Antiepileptics (e.g., phenytoin, phenobarbital): may modestly decrease hormone exposure.
  • Antifungals (e.g., ketoconazole): can increase estrogen levels, raising side‑effect potential.
  • SSRIs (e.g., fluoxetine): may enhance mood‑related adverse effects and require observation.

Frequently Asked Questions

Marvelon is prescribed as a combined oral contraceptive to prevent unintended pregnancy in women of reproductive age. It works by suppressing ovulation and creating cervical mucus conditions that hinder sperm penetration, providing reliable birth control when taken daily as directed.

The combination of desogestrel (a progestogen) and ethinylestradiol (an estrogen) suppresses the mid‑cycle luteinising hormone surge, preventing ovulation. It also thickens cervical mucus and induces endometrial changes that make implantation unlikely, delivering a multi‑mechanistic contraceptive effect.

The dosing regimen for Marvelon is determined by the prescribing clinician. Typically, the product is taken as one tablet daily for 21 consecutive days followed by a hormone‑free interval, but the exact schedule should be confirmed with a qualified healthcare professional.

Marvelon is contraindicated during pregnancy (Category X) and should not be started in women who are pregnant. While limited data exist for breastfeeding, most guidelines advise caution; a prescriber should evaluate the risk‑benefit balance before use in lactating mothers.

To order Marvelon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Marvelon contains a low‑dose estrogen (30 µg ethinylestradiol) and a third‑generation progestogen (150 µg desogestrel), offering a favorable bleeding profile and reduced androgenic side effects compared with older formulations. Efficacy is comparable to other COCs, but individual tolerability may differ.

Marvelon tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the medication out of reach of children and avoid storing in bathrooms or other humid environments.

Marvelon is taken orally, with or without food, as a single tablet each day. Consistent daily intake at the same time each day maximises contraceptive reliability. If a dose is missed, follow the product’s missed‑dose instructions or consult a healthcare provider.

Serious risks include venous or arterial thromboembolism, hypertension, liver dysfunction, and severe allergic reactions. Women should seek immediate medical attention for symptoms such as unexplained leg pain, chest discomfort, severe headache, visual changes, or signs of an allergic reaction.

Marvelon is contraindicated in women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, known estrogen‑dependent tumors, severe liver disease, or are smokers over 35 years of age. A thorough medical assessment is required before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Desogestrel, Ethinylestradiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT